WEBVTT

1
00:00:00.000 --> 00:00:08.608
>> A HIGH-TECH PHARMA COMPANY
RECENTLY INKED A DEAL TO BUILD A
$72-MILLION-DOLLAR PRODUCTION
FACILITY AT THE PURDUE RESEARCH

2
00:00:08.608 --> 00:00:16.483
PARK OF INDIANAPOLIS. ADVANCED
ACCELERATOR APPLICATIONS IS A
SUBSIDIARY OF SWITZERLAND-BASED
PHARMACEUTICAL GIANT NOVARTIS

3
00:00:16.483 --> 00:00:23.556
AND HAS AN IMPORTANT INDIANA
CONNECTION.
BUSINESS OF HEALTH REPORTER
KYLIE VELETA HAS MORE.

4
00:00:23.556 --> 00:00:28.661
>> THANK YOU, GERRY.
NOVARTIS AG ACQUIRED WEST
LAFAYETTE-BASED ENDOCYTE FOR
TWO-BILLION DOLLARS IN 2018.

5
00:00:28.661 --> 00:00:34.834
IT'S THE LARGEST-EVER
ACQUISITION OF AN INDIANA LIFE
SCIENCES COMPANY. ENDOCYTE IS
BASED ON TECHNOLOGY DISCOVERED

6
00:00:34.834 --> 00:00:44.043
BY DR. PHILIP LOW AT PURDUE
UNIVERSITY AND THAT INDIANA
CONNECTION WAS A MAJOR REASON
THAT ADVANCED ACCELERATOR

7
00:00:44.043 --> 00:00:48.681
APPLICATIONS, OR AAA, CHOSE
INDIANA FOR ITS NEW PRODUCTION
FACILITY.
AAA IS A SIGNIFICANT PIECE OF

8
00:00:48.681 --> 00:01:00.527
NOVARTIS' ONCOLOGY PORTFOLIO.
MIKE ROSSI IS THE USA GENERAL
MANAGER FOR AAA. HE JOINS ME NOW
TO TELL US MORE ABOUT THE

9
00:01:00.527 --> 00:01:09.035
HIGH-TECH FACILITY AND WHAT IT
WILL BE MAKING.
MIKE, THANK YOU FOR BEING ON THE
SHOW TODAY. THEY TARGET

10
00:01:09.035 --> 00:01:19.679
THERAPIES WHICH ARE REALLY ON
THE CUTTING EDGE OF CANCER
TREATMENT. CAN YOU EXPLAIN FIRST
OF ALL WHAT ARE RADIO THERAPIES?

11
00:01:19.679 --> 00:01:29.055
>> ABSOLUTELY. RLT, AS WE REFER
TO IT IS A FORM OF TARGETED
PRECISION MEDICINE, THAT
COMBINES A TARGETED COMPOUND OR

12
00:01:29.055 --> 00:01:43.236
DRUG WITH A RADIOACTIVE PARTIAL
THAT BIND TO MARKERS ON CANCER
CELLS DELIVERING A RADIO ISOTOPE
THAT DAMAGES AND KILLS CANCER

13
00:01:43.236 --> 00:01:51.478
CELLS?
>> IT GENERATED $336 MILLION IN
THE FIRST NINE MONTHS OF 2020.
REALLY INTERESTING, ONCE IT IS

14
00:01:51.478 --> 00:02:01.721
MANUFACTURED, YOU ONLY HAVE 72
HOURS TO GET IT IN THE PATIENT.
KIND OF MIND BOGGLING. CAN YOU
EXPLAIN WHY THAT FACT HELPED

15
00:02:01.721 --> 00:02:13.566
LEAD YOU TO INDIANAPOLIS?
>> ABSOLUTELY. THAT'S A UNIQUE
PART OF THE DRUG, IN THAT IT HAS
SUCH A SHORT SHELF LIFE. IN THIS

16
00:02:13.566 --> 00:02:20.373
LOCATION, CLOSE TO THE
INTERNATIONAL AIRPORT, MAJOR
TRANSPORTATION HUBS AROUND THE
FACILITY ENSURES THAT YOUR

17
00:02:20.373 --> 00:02:26.746
MEDICINES CAN BE ADMINISTERED TO
PATIENTS ANYWHERE IN AMERICA
WITHIN 72 HOURS. FOR US, THAT'S
EXTREMELY IMPORTANT, BEING ABLE

18
00:02:26.746 --> 00:02:39.325
TO REACH PATIENTS IN A TIMELY
MANNER TO DELIVER THE THERAPY.
>> OKAY. SO IN ADDITION TO
GEOGRAPHY, AN IMPORTANT BUSINESS

19
00:02:39.325 --> 00:02:48.601
CONNECTION, NOVARTIS ACQUIRED
ENDOCYTE IN 2018. HOW IMPORTANT
WAS THAT RELATIONSHIP IN AAA'S
DECISION TO COME TO INDIANA?

20
00:02:48.601 --> 00:02:56.075
>> IT WAS MASSIVELY IMPORTANT.
OUR TECHNOLOGY WORKFORCE, THAT
IS PART OF THE ENDOCYTE
ACQUISITION REALLY UNDERSTANDS

21
00:02:56.075 --> 00:03:03.249
THE THERAPY AND HAS A GREAT
AMOUNT OF EXPERTISE. THEY WERE
ALSO EXTREMELY EMBEDDED INTO THE
COMMUNITY IN INDIANA. FOR US, WE

22
00:03:03.249 --> 00:03:10.723
WANTED TO EXPAND ON THAT
RELATIONSHIP, AND CONTINUE TO
RECRUIT HIGHLY EDUCATED AND
EXPERIENCED TALENTED LABOR FORCE

23
00:03:10.723 --> 00:03:18.364
THAT INDIANA HAS TO OFFER.
>> AND I KNOW PURDUE UNIVERSITY
IS AN INTERESTING PIECE OF THAT,
TOO, AS FAR AS THE NUCLEAR

24
00:03:18.364 --> 00:03:28.107
PHARMACY PROGRAM.
>> THEY ARE. THEY'RE ONE OF THE
ONLY PHARMACY SCHOOLS IN THE
COUNTRY THAT OFFERS NUCLEAR

25
00:03:28.107 --> 00:03:35.315
PHARMACY TO OFFER PHARMACISTS.
FOR US THAT ENSURES A TALENTED
WORKFORCE THAT WILL BE
SPECIALIZED IN NUCLEAR MEDICINE.

26
00:03:35.315 --> 00:03:42.989
>> ALL RIGHT. DO YOU EXPECT IN
THE FUTURE THAT ENDOCYTE'S
PROSTATE CANCER TREATMENT COULD
BE MANUFACTURED AT THIS FACILITY

27
00:03:42.989 --> 00:03:51.998
IN INDIANAPOLIS WHEN IT REACHES
THAT POINT?
>> IT IS. OUR FACILITY IS REALLY
FOCUSED ON MANUFACTURING

28
00:03:51.998 --> 00:04:00.974
MULTIPLE RADIO LIGAN PRODUCTS IN
THE FUTURE. WE START WITH A
PRODUCT AND MOVE ON TO PIPELINE
AND ADDITIONAL PRODUCTS IN THE

29
00:04:00.974 --> 00:04:10.984
FUTURE. THE FACILITY ITSELF WILL
BE ABLE TO PRODUCE 85,000 DOSES
PER YEAR OF RADIO LIGAN THERAPY
IN ITS ORIGINAL CONFIGURATION

30
00:04:10.984 --> 00:04:23.730
WITH ROOM TO EXPAND.
>> THE INITIAL INVESTMENT,
$72 MILLION, 50 JOBS. THAT'S A
STARTING POINT.

31
00:04:23.730 --> 00:04:32.905
>> IT IS. OUR INITIAL FACILITY,
WE ACQUIRED 16 ACRES. WE'RE
USING A SMALL PORTION OF THAT TO
BUILD THE INITIAL 60,000 SQUARE

32
00:04:32.905 --> 00:04:40.580
FOOT FACILITY. WE'LL HAVE
PRODUCTION LINES IN THAT. IT WAS
IMPORTANT FOR US TO HAVE THE
LAND SURROUNDING SO WE COULD

33
00:04:40.580 --> 00:04:49.455
EXPAND AND GROW THE FACILITY.
AND WE EXPECT TO EMPLOY UP TO 90
ASSOCIATES IN FULL SWING.
>> YOUR A PHARMACISTS BY

34
00:04:49.455 --> 00:04:56.896
TRAINING. HOW EXCITED ARE YOU
JUST ABOUT HAVING THIS NEW
CUTTING-EDGE THERAPY, AND OTHERS
COMING IN THE PIPELINE, TO

35
00:04:56.896 --> 00:05:04.070
REALLY IMPACT THE LIVES OF
CANCER PATIENTS.
>> IT'S, YOU KNOW, FOR ME, MY
LIFE'S MISSION HAS BEE IN

36
00:05:04.070 --> 00:05:11.544
HEALTHCARE. AND AS A HEALTHCARE
PROFESSIONAL FIRST AND FOREMOST,
I PUT THE PATIENTS AHEAD OF
EVERYTHING ELSE. SO FOR ME, I'VE

37
00:05:11.544 --> 00:05:19.385
DEDICATED MY ENTIRE CAREER TO
NUCLEAR MEDICINE AND
RADIOPHARMACEUTICALS, AND FOR ME
TO BE PARTICIPATING IN THE

38
00:05:19.385 --> 00:05:29.128
LAUNCH OF A BRAND-NEW PLATFORM
TO IMPACT ONCOLOGY PATIENTS IS
REALLY THE PINNACLE OF MY CAREER
AND MAKING AND CONTRIBUTING TO

39
00:05:29.128 --> 00:05:37.537
MAKING THE LIVES OF CANCER
PATIENTS THAT MUCH BETTER.
>> AND ABLE TO EXECUTE THIS DEAL
AMID THE PANDEMIC. YOU INKED IT

40
00:05:37.537 --> 00:05:44.544
JUST AS THE PANDEMIC WAS
STARTING TO TAKE ITS GRIP. GLAD
YOU WERE ABLE TO POWER THROUGH,
WELCOME TO INDIANA, WE'LL BE

41
00:05:44.544 --> 00:05:49.615
FOLLOWING YOU, THANKS FOR BEING
ON THE SHOW TODAY.
>> THANKS, GLAD TO BE HERE,
THANK YOU FOR THIS OPPORTUNITY